ReviewPediatric research2018
Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review.
Review in Pediatric research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- Hypoxic TCs-preconditioned MSCs ameliorate acute lung injury via enhanced Treg recruitment and function through CXCL5/6-CXCR1 axis.Stem cell research & therapy · 2025Article
- Exploring the therapeutic potential of MSC-derived secretomes in neonatal care: focus on BPD and NEC.Stem cell research & therapy · 2025Review
- The Destructive Cycle in Bronchopulmonary Dysplasia: The Rationale for Systems Pharmacology Therapeutics.Antioxidants (Basel, Switzerland) · 2025Review
- Stem cell-derived extracellular vesicles: a potential intervention for Bronchopulmonary Dysplasia.Pediatric research · 2025Review
- Longitudinal transcriptomic analysis of the hyperoxia-exposed preterm rabbit as a model of BPD.Frontiers in pediatrics · 2025Article
- Temporal Dynamics of Oxidative Stress and Inflammation in Bronchopulmonary Dysplasia.International journal of molecular sciences · 2024Review
- Role of Myeloperoxidase, Oxidative Stress, and Inflammation in Bronchopulmonary Dysplasia.Antioxidants (Basel, Switzerland) · 2024Review
- Association of Fetal Lung Development Disorders with Adult Diseases: A Comprehensive Review.Journal of personalized medicine · 2024Review
- Olfactory mucosa mesenchymal stem cells alleviate pulmonary fibrosis via the immunomodulation and reduction of inflammation.BMC pulmonary medicine · 2024Article
- Stem cells as a therapeutic avenue for active and long-term complications of Necrotizing Enterocolitis.Seminars in pediatric surgery · 2023Article
- Stem cell derived therapies to preserve and repair the developing intestine.Seminars in perinatology · 2023Article
- Mesenchymal stromal/stem cells and bronchopulmonary dysplasia.Frontiers in cell and developmental biology · 2023Review
- Reproductive and Developmental Toxicity Assessment of Human Umbilical Cord Mesenchymal Stem Cells in Rats.Frontiers in cell and developmental biology · 2022Article
- Mesenchymal stem cells from different sources show distinct therapeutic effects in hyperoxia-induced bronchopulmonary dysplasia in rats.Journal of cellular and molecular medicine · 2021Article
- [Current state of the obesity research: genetic aspects, the role of microbiome, and susceptibility to COVID-19].Problemy endokrinologii · 2021Review
- Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants.Journal of translational medicine · 2020Article
- Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics.International journal of molecular sciences · 2020Review
- Intratracheal Transplantation of Amnion-Derived Mesenchymal Stem Cells Ameliorates Hyperoxia-Induced Neonatal Hyperoxic Lung Injury via Aminoacyl-Peptide Hydrolase.International journal of stem cells · 2020Article
- Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials.World journal of stem cells · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Advances in neonatal medicine have led to increased survival of infants born at the limits of viability, resulting in an increased incidence of bronchopulmonary dysplasia (BPD). BPD is a chronic lung disease of premature infants characterized by the arrest of alveolarization, fibroblast activation, and inflammation. BPD leads to significant morbidity and mortality in the neonatal period and is one of the leading causes of chronic lung disease in children. The past decade has brought a surge of trials investigating cellular therapies for the treatment of pulmonary diseases. Mesenchymal stem cells (MSCs) are of particular interest because of their ease of isolation, low immunogenicity, and anti-inflammatory and reparative properties. Clinical trials of MSCs have demonstrated short-term safety and tolerability; however, studies have also shown populations of MSCs with adverse pro-inflammatory and myofibroblastic characteristics. Cell-based therapies may represent the next breakthrough therapy for the treatment of BPD, however, there remain barriers to implementation as well as gaps in knowledge of the role of endogenous MSCs in the pathogenesis of BPD. Concurrent high-quality basic science, translational, and clinical studies investigating the fundamental pathophysiology underlying BPD, therapeutic mechanisms of exogenous MSCs, and logistics of translating cellular therapies will be important areas of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.